Clinical Trial Update: Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for immunotherapy using 41BB-selected tumor infiltrating lymphocytes in metastatic melanoma; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma, Skin Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-09-19